Neomer Diagnostics
Jan 2022
·
1 min read
Overview
Co-founded Neomer Diagnostics in 2022 as Chief Technical Officer to translate patented nullomer research into a clinical cancer detection platform. The company developed machine learning pipelines for detecting cancer from liquid biopsies.
Role & Achievements
As CTO, I:
- Developed ML pipeline in Bash, Julia, Python, and Slurm for cancer detection from liquid biopsies
- Achieved AUC ranging from 0.89 to 0.94 in lung and ovarian cancers
- Established regulatory roadmap for clinical validation and FDA approval
- Secured $850K in translational research funding
- Led technical team and coordinated with clinical partners
Technology
The platform leveraged sequences absent from the human genome (nullomers) as biomarkers for cancer detection. Machine learning models were trained on cell-free DNA and RNA data from liquid biopsies to distinguish cancer patients from healthy controls.
Clinical Applications
- Early cancer detection
- Cancer screening in high-risk populations
- Monitoring treatment response
- Detecting minimal residual disease
Funding & Recognition
- Secured $850K in translational research funding
- Patent portfolio covering nullomer-based diagnostics
- Partnerships with clinical institutions
Period
January 2022 - May 2023
Authors
Ioannis Mouratidis
(he/him)
Senior Research Engineer/Scientist Associate
Machine learning and genomics researcher with 35 publications (10 first or senior author).
Co-founded AI-driven cancer biomarker startup, authored grants securing $4M+ in competitive funding
and currently lead a 5-member team with a focus in developing novel computational methods and testing
the capabilities and safety profiles of biological foundation models.